Bayer and Aignostics GmbH have announced a strategic partnership focusing on AI-powered precision oncology drug research and development. Aignostics, a spin-off from Charité-Universitätsmedizin Berlin, specializes in computational pathology to decipher complex biomedical data.
The collaboration aims to create a target identification platform utilizing Aignostics’ technology and multimodal patient cohorts alongside Bayer’s expertise in oncology therapy development. This includes developing AI-driven computational pathology algorithms to integrate baseline pathology and clinical data for improved patient identification and selection in trials.
The partnership’s primary goal is to identify cancer targets with a strong disease link through AI models applied to diverse patient data, aiming to expedite oncology program development. This approach targets challenges in target discovery and disease heterogeneity.
Christian Rommel, from Bayer Pharmaceuticals, highlighted the potential of integrating AI and multimodal pathology in drug development. This collaboration will harness Aignostics’ technology and longitudinal patient datasets to discover new oncology targets for high unmet medical needs. The agreement entails collaboration on multiple discovery programs and initiation of at least two target identification programs.
Viktor Matyas, CEO of Aignostics GmbH, expressed excitement about advancing healthcare through the fusion of their technology with Bayer’s drug discovery and clinical development expertise. Aignostics will receive upfront and milestone payments, along with royalties on commercialized therapies resulting from the collaboration.
Established in 2018, Aignostics focuses on precision medicine development, backed by leading VC investors and operations in Berlin and New York. Bayer, a global life science enterprise, is committed to sustainable development and innovation.
Both parties are optimistic about translating AI’s potential into impactful healthcare solutions. Bayer’s mission aligns with global health challenges, while Aignostics aims to revolutionize precision medicine through data-driven approaches.